Kelm M, Feelisch M, Krebber T, Motz W, Strauer B E
Department of Cardiology, Heinrich-Heine University, Düsseldorf, Germany.
J Cardiovasc Pharmacol. 1992;20 Suppl 12:S183-6. doi: 10.1097/00005344-199204002-00051.
Nitric oxide (NO) plays an important role in the regulation of coronary vascular resistance. The aim of the present study was to evaluate the role of NO in the regulation of coronary vascular resistance in isolated hearts from normo- and hypertensive rats, which served as a model for arterial hypertension and hypertensive heart disease. Isolated hearts from normotensive Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs) were perfused at constant flow, whereas the release of NO into the coronary circulation was measured simultaneously by the oxyhemoglobin technique. Bradykinin, an endothelium-dependent vasodilator, concentration-dependently decreased the coronary perfusion pressure in SHRs by 47 +/- 3% and in WKY rats by 35 +/- 6%. In parallel, the basal NO release increased in both groups, maximally by 154 and 118 pmol/min in SHRs and WKY rats, respectively. Amounts of released NO were sufficient to account for the bradykinin-induced coronary vasodilation. These data indicate that coronary resistance vessels in hearts from hypertensive compared to normotensive rats exhibit a higher sensitivity to the endothelium-dependent vasodilator bradykinin, paralleled by a higher release of NO into the coronary circulation. An enhanced endothelial NO synthesis within the coronary circulation may represent a compensatory mechanism aimed at counterregulating distinct changes in vascular reactivity occurring in arterial hypertension.
一氧化氮(NO)在冠状动脉血管阻力调节中起重要作用。本研究的目的是评估NO在正常血压和高血压大鼠离体心脏冠状动脉血管阻力调节中的作用,这些大鼠作为动脉高血压和高血压性心脏病的模型。以恒定流量灌注正常血压的Wistar-Kyoto(WKY)大鼠和自发性高血压大鼠(SHR)的离体心脏,同时采用氧合血红蛋白技术测量冠状动脉循环中NO的释放。缓激肽是一种内皮依赖性血管舒张剂,它使SHR的冠状动脉灌注压浓度依赖性降低47±3%,使WKY大鼠降低35±6%。同时,两组的基础NO释放均增加,SHR和WKY大鼠分别最大增加154和118 pmol/分钟。释放的NO量足以解释缓激肽诱导的冠状动脉血管舒张。这些数据表明,与正常血压大鼠相比,高血压大鼠心脏中的冠状动脉阻力血管对内皮依赖性血管舒张剂缓激肽表现出更高的敏感性,同时冠状动脉循环中NO的释放也更高。冠状动脉循环中内皮型NO合成增强可能是一种旨在对抗动脉高血压中血管反应性明显变化的代偿机制。